NEW YORK (GenomeWeb) — Luminex executives this week provided investors with an update on the progress of Aries, the sample-to-answer molecular testing platform that the company plans to launch in Europe later this year and the US next year.

In addition, executives discussed Luminex's new xTAG multiplex assay technology and provided some insight as to how it is expected — both alone and in combination with a future iteration of the Aries platform — to drive continued molecular diagnostics growth at the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.